Boehringer Ingelheim is making a bid in oncolytic viruses in a deal with preclinical ViraTherapeutics that’s worth up to €210 million ($236 million). As part of the deal, the pharma gains the right to buy the biotech after Phase 1 development is finished.

The partners will work together to develop a next-gen oncolytic virus therapy platform, as well as to advance ViraTherapeutic’s lead candidate VSV-GP (Vesicular Stomatitis Virus (VSV) glycoprotein (GP)) alone and in combination with other treatements.

“Oncolytic viruses are among the most promising new therapy approaches in cancer research and the technology developed by ViraTherapeutics may offer significant advantages compared to others currently under development,” said Boehringer Ingelheim board member Dr. Michel Pairet.